Total receipts for the quarter ended Sept. 30 totaled $264.8 million, up from $230.4 million during the same period one year ago. These results reflect strong demand from US and Asian pharma and industry for all Waters product, as well as improved business conditions in
Third-quarter R&D spending increased to $17 million from $15.1 million last year.
Waters' net income for the quarter increased to $51.9 million, or $.43 per basic share, from $36.4 million, or $.30 per basic share.
As of Oct. 2, Waters had $471.2 million in cash and cash equivalents.